A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose "Wearing-Off" (TOZ-PD)

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose "Wearing-Off" (TOZ-PD)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Tozadenant (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms TOZ-PD
  • Sponsors Acorda Therapeutics; Biotie Therapies Corp.
  • Most Recent Events

    • 08 Jun 2017 Interim results (n=264) evaluating baseline characteristics of this trial presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 06 Jun 2017 Baseline characteristics of patients enrolled to date in this trial will be presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS), according to an Acorda Therapeutics media release.
    • 09 Jan 2017 According to an Acorda Therapeutics media release, topline data are expected in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top